Page last updated: 2024-11-05

hyaluronoglucosaminidase

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Hyaluronoglucosaminidase: An enzyme that catalyzes the random hydrolysis of 1,4-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate. (From Enzyme Nomenclature, 1992) There has been use as ANTINEOPLASTIC AGENTS to limit NEOPLASM METASTASIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

kinetin riboside: preferentially induces apoptosis by modulating Bcl-2 family proteins and caspase-3 in cancer cells; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91820602
MeSH IDM0010666
PubMed CID20345
CHEMBL ID411066
CHEBI ID95050
SCHEMBL ID3190252
MeSH IDM0010666

Synonyms (74)

Synonym
hyaluronidase
9001-54-1
hyaluronoglucosaminidase
S4424
37326-33-3
AKOS025293742
6-(3,3-dimethyl-2-methylideneindol-1-yl)hexanoic acid;hydrobromide
hyaluronidase from bovine testes,
MLS002207023
kinetin-9-riboside
smr001223878
einecs 224-389-3
n-(2-furanylmethyl)-1h-purin-6-amine riboside
nsc 120958
brn 0059588
ribosylkinetin
n-(2-furanylmethyl)adenosine
n(sup 6)-furfuryladenosine
BRD-K94325918-001-02-0
n6-furfuryladenosine
4338-47-0
6-furfurylaminopurine riboside
kinetin riboside
DIVK1C_006647
SDCCGMLS-0066656.P001
SPECTRUM_001277
SPECTRUM4_001930
BSPBIO_002802
SPECTRUM5_000687
SMP1_000170
kinetin riboside, proapoptotic anitproliferative plant growth regulator
NCGC00142491-01
KBIOGR_002280
KBIO2_001757
KBIO3_002022
KBIO2_004325
KBIOSS_001757
KBIO1_001591
KBIO2_006893
SPBIO_001345
SPECPLUS_000551
SPECTRUM2_001453
SPECTRUM3_001101
NCGC00142491-02
NCGC00142491-03
(2r,3r,4s,5r)-2-(6-(furan-2-ylmethylamino)-9h-purin-9-yl)-5-(hydroxymethyl)-tetrahydrofuran-3,4-diol
bdbm50241447
CHEMBL411066 ,
(2r,3r,4s,5r)-2-[6-(furan-2-ylmethylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
n6-(2-furanylmethyl)-adenosine
CAGLGYNQQSIUGX-SDBHATRESA-N
(3s,2r,4r,5r)-5-{6-[(2-furylmethyl)amino]purin-9-yl}-2-(hydroxymethyl)oxolane- 3,4-diol
CCG-38867
NCGC00017361-03
NCGC00017361-02
NCGC00017361-04
4-26-00-03686 (beilstein handbook reference)
SCHEMBL3190252
AKOS024282559
mfcd00037987
CHEBI:95050
sr-05000002609
SR-05000002609-1
(-)-kinetin riboside
CS-6377
HY-101055
(2r,3r,4s,5r)-2-(6-(furan-2-ylmethylamino)-9h-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
DTXSID20874669
Q27166818
(2r,3r,4s,5r)-2-[6-(2-furanylmethylamino)-9-purinyl]-5-(hydroxymethyl)oxolane-3,4-diol
F12926
(2r,3r,4s,5r)-2-(6-((furan-2-ylmethyl)amino)-9h-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
BRD-K94325918-001-05-3
AS-76879

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" On an equal weight basis, VCR proved to be significantly more toxic than either VBL or VDS (P less than ."( Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse.
Alberts, DS; Dorr, RT, 1985
)
0.27
" Of the rabbit eyes injected with the Wydase vehicle (n = 19), 68% had toxic changes."( Corneal toxicity of intraocular hyaluronidase.
Duncan, J; Duncan, KG; Equi, RA; Jumper, JM; McCauley, MB; Schwartz, DM, 2002
)
0.31
" The noncytotoxic nature should make T-PSS safe for vaginal use."( Efficacy and safety of a new vaginal contraceptive antimicrobial formulation containing high molecular weight poly(sodium 4-styrenesulfonate).
Anderson, RA; Chany, C; Cooper, M; Diao, XH; Doncel, GF; Feathergill, K; Herold, B; Rencher, WF; Waller, DP; Zaneveld, LJ, 2002
)
0.31
" Two patients in the levobupivacaine group experienced serious adverse events, but neither was considered related to the study medication."( The efficacy and safety of 0.75% levobupivacaine vs 0.75% bupivacaine for peribulbar anaesthesia.
Birt, DJ; Cummings, GC, 2003
)
0.32
"Levobupivacaine and bupivacaine are equally successful in achieving clinically satisfactory peribulbar anaesthesia with few adverse effects."( The efficacy and safety of 0.75% levobupivacaine vs 0.75% bupivacaine for peribulbar anaesthesia.
Birt, DJ; Cummings, GC, 2003
)
0.32
" Thus, properly optimized EP-assisted plasmid-based gene transfer is a feasible, efficient, and safe method of gene replacement therapy for dystrophin deficiency of muscle but readministration may be necessary."( Factors influencing the efficacy, longevity, and safety of electroporation-assisted plasmid-based gene transfer into mouse muscles.
Gilbert, R; Guo, A; Karpati, G; Larochelle, N; Liu, AB; Lochmuller, H; Lu, Y; Molnar, MJ; Nalbantoglu, J; Orlopp, K; Petrof, BJ, 2004
)
0.32
" Assessments included history, ocular symptoms, adverse events, BCVA, intraocular pressure, external eye examination, slit-lamp biomicroscopy, fundus examination, B-scan ultrasonography, and fundus photography."( Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage.
de Smet, MD; Grillone, LR; Kuppermann, BD; Thomas, EL, 2005
)
0.33
" Iritis was the most common ocular adverse event, occurring in 33."( Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage.
de Smet, MD; Grillone, LR; Kuppermann, BD; Thomas, EL, 2005
)
0.33
" Iritis manifesting as an acute self limited inflammation was the most common adverse event, occurred in a dose response fashion, but was not noted to result in a serious adverse event in any hyaluronidase treated eye."( Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage.
de Smet, MD; Grillone, LR; Kuppermann, BD; Thomas, EL, 2005
)
0.33
" Secondary parameters were akinesia at later times, additional injections, ptosis of the upper eyelid, time to reach complete anesthesia, assessment of pain using a visual analog scale, assessment of efficacy and tolerability by the patient and the surgeon, and adverse events."( Efficacy and safety of hyaluronidase 75 IU as an adjuvant to mepivacaine for retrobulbar anesthesia in cataract surgery.
Kampik, A; Nentwich, MM; Pinter, F; Remy, M; Schönfeld, CL, 2008
)
0.35
" No adverse events occurred in either group."( Efficacy and safety of hyaluronidase 75 IU as an adjuvant to mepivacaine for retrobulbar anesthesia in cataract surgery.
Kampik, A; Nentwich, MM; Pinter, F; Remy, M; Schönfeld, CL, 2008
)
0.35
" Subjects were monitored for adverse events (AEs); blood samples were obtained (Part 2 only) during 48 hours post-dosing for ceftriaxone bioanalysis."( Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers.
Battikha, J; Harb, G; Lebel, F; Thackara, JW, 2010
)
0.36
" The results were all negative, excluding allergy as the aetiology of this toxic periorbital syndrome, in at least these four patients."( Hyaluronidase toxicity: a possible cause of postoperative periorbital inflammation.
Goggin, M; Lake, DB; Leatherbarrow, B; Malhotra, R; Moore, S; Norris, JH; Selva, D; Zamora-Alejo, K, 2013
)
0.39
"The consecutive patients using HA attending to our clinic in the past 3 years were divided into 3 categories, according to the time of presentation of the adverse reactions: immediate, early, and late-onset complications."( Undesirable effects after treatment with dermal fillers.
Camacho-Martínez, FM; Rodrigues-Barata, AR, 2013
)
0.39
" Physicians need to be aware of these possible adverse events in order to establish proper treatment and prevent scarring or other sequelae."( Undesirable effects after treatment with dermal fillers.
Camacho-Martínez, FM; Rodrigues-Barata, AR, 2013
)
0.39
"7 subject-years of IGHy exposure, 2005 adverse events (AEs) (10."( Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
Church, J; Engl, W; Gelmont, D; Grant, AJ; Gupta, S; Kobrynski, L; Leibl, H; Melamed, I; Puck, J; Ratnayake, A; Richmond, WG; Rubinstein, A; Sharkhawy, M; Stein, MR; Wasserman, RL; Yel, L, 2016
)
0.43
"Long-term replacement therapy with IGHy was safe and effective in 83 pediatric and adult subjects with PIDD."( Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
Church, J; Engl, W; Gelmont, D; Grant, AJ; Gupta, S; Kobrynski, L; Leibl, H; Melamed, I; Puck, J; Ratnayake, A; Richmond, WG; Rubinstein, A; Sharkhawy, M; Stein, MR; Wasserman, RL; Yel, L, 2016
)
0.43
" No serious adverse drug reaction (ADR) was reported, and rates of local and systemic ADRs were low (0."( Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.
Doralt, J; Engl, W; Gelmont, D; Gupta, S; Kobrynski, L; Leibl, H; Melamed, I; Puck, J; Sharkhawy, M; Wasserman, RL; Yel, L, 2016
)
0.43
" However, with careful low pressure, low volume injection technique, and adequate preparation for treatment of acute vascular events, the risk is quite manageable and the vast majority of adverse events are very treatable with an excellent prognosis, with a few exceptions."( New High Dose Pulsed Hyaluronidase Protocol for Hyaluronic Acid Filler Vascular Adverse Events.
DeLorenzi, C, 2017
)
0.46
" A comprehensive knowledge of facial anatomy, including structural positioning of facial arteries and veins, and an extensive knowledge of HA products available for injection procedures, combined with best practice protocols, will assist to prevent adverse events."( Hyaluronidase: Understanding Its Properties and Clinical Application for Cosmetic Injection Adverse Events.
Harrison, J; Rhodes, O,
)
0.13
" Fifty-eight adverse events were reported among 130 patients undergoing endoscopic adhesiolysis, and 19 among the 110 undergoing percutaneous adhesiolysis."( Efficacy, Effectiveness, Safety, and Cost-effectiveness of Epidural Adhesiolysis for Treating Failed Back Surgery Syndrome. A Systematic Review.
Brito-García, N; Del Pino-Sedeño, T; García-Pérez, L; Imaz-Iglesia, I; Kovacs, FM; Pérez-Ramos, J; Serrano-Aguilar, P, 2019
)
0.51
"Hyaluronic acid fillers are known for a reliable safety profile, but complications do occur, even serious vascular adverse events."( Early ultrasound for diagnosis and treatment of vascular adverse events with hyaluronic acid fillers.
Kadouch, J; Schelke, LW; Swift, A; Velthuis, P, 2023
)
0.91
"To improve the treatment outcome after a vascular adverse event with use of hyaluronic acid filler treatments."( Early ultrasound for diagnosis and treatment of vascular adverse events with hyaluronic acid fillers.
Kadouch, J; Schelke, LW; Swift, A; Velthuis, P, 2023
)
0.91
"Because the use of duplex ultrasonography adds extra essential information, its use may become an integral part of the prevention and treatment of injection adverse events."( Early ultrasound for diagnosis and treatment of vascular adverse events with hyaluronic acid fillers.
Kadouch, J; Schelke, LW; Swift, A; Velthuis, P, 2023
)
0.91
" Thus, the treatment provided must not only be effective but also safe and well tolerated."( Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(
Angelotti, F; Capecchi, R; Giannini, D; Mazzarella, O; Migliorini, P; Rocchi, V, 2020
)
0.56
" However, adverse effects of hyaluronidase treatment, such as increased rates of degeneration and parthenogenesis, have been found after treatment of human and mouse oocytes."( Mechanism of the adverse effect of hyaluronidase used for oocyte denudation on early development of bovine embryos.
Ashibe, S; Irisawa, K; Nagao, Y; Yokawa, K, 2021
)
0.62
" Adverse events (AEs) were generally consistent with previous reports for docetaxel monotherapy in NSCLC, except for higher incidence of musculoskeletal events, including myalgias, with PVHA plus docetaxel."( Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non-small cell lung cancer.
Baumgart, M; Fathallah, AM; Gabrail, N; Heineman, T; Mager, DE; Maneval, DC; Nanavati, C; Sekulovich, RE; Van Wart, SA, 2021
)
0.62
" There were no serious or dose-limiting adverse events in either study."( Safety, Tolerability, and Pharmacokinetics of High-Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers.
Blondeau, K; Brooks, L; Carrasco-Triguero, M; Chesterman, A; Deshmukh, A; Dolton, MJ; Hu, N; Kerchner, GA; Moein, A; Ostrowitzki, S; Peng, K; Quartino, A; Roden, A; Sink, KM; Smith, J; Waitz, A; Wetzel-Smith, MK, 2021
)
0.62
" The immunogenicity profile demonstrates no adverse effects associated with treatment-emergent rHuPH20 antibody responses."( Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery.
Kang, DW; Knowles, SP; LaBarre, MJ; Printz, MA; Tannenbaum, RP, 2021
)
0.62
" In addition, there were no cases of adverse events associated with taking the drug Longidaza."( [An observational randomized study of the efficacy and safety of the drug Longidase, vaginal and rectal suppositories 3000 iu in the treatment of patients with symptoms of the lower urinary tract on the background of benign prostatic hyperplasia].
Gyaurgiev, TA; Kuzmenko, AV; Kuzmenko, VV; Vinnik, YY, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" IFN-alpha 2) either in saline, human albumin (ALB) solution (4, 7 and 10% final concentrations), or in a solution containing 75 U of hyaluronidase, modified the pharmacokinetic parameters calculated from the IFN plasma levels."( The lymphatic route--II. Pharmacokinetics of human recombinant interferon-alpha 2 injected with albumin as a retarder in rabbits.
Bianchi, E; Bocci, V; Muscettola, M; Naldini, A; Segre, G, 1986
)
0.27
" Maximum plasma concentration (Cmax) and time to reach Cmax (Tmax) were obtained for all the patients except one who needed a supplementary injection and was excluded from the study."( The role of hyaluronidase on lidocaine and bupivacaine pharmacokinetics after peribulbar blockade.
Adenis, JP; Benrhaiem, M; Debord, J; Feiss, P; Lachatre, G; Lotfi, H; Nathan, N; Rigaud, G, 1996
)
0.29
" Pharmacokinetic parameters included peak serum insulin concentration (C(max)), time to C(max) (t(max)), and area under the curve (AUC) of serum concentration versus time."( Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase.
Bilinsky, IP; Frost, GI; Muchmore, DB; Sugarman, BJ; Vaughn, DE; Vick, AM; Yocum, RC, 2009
)
0.35
"This study was designed to test the hypothesis that co-administration of recombinant human hyaluronidase (rHuPH20) with regular insulin or insulin lispro will reduce intrasubject variability in pharmacokinetic end points compared with lispro alone."( Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers.
Hompesch, M; Ludington, EA; Morrow, L; Muchmore, DB; Vaughn, DE, 2011
)
0.37
" Intrasubject variability for regular insulin with rHuPH20 for most pharmacokinetic parameters was similar to the variability of lispro alone, although variability in early exposure was significantly reduced."( Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers.
Hompesch, M; Ludington, EA; Morrow, L; Muchmore, DB; Vaughn, DE, 2011
)
0.37
" Geometric mean ratio (GMR) for area under the plasma concentration-time curve from zero to infinity (AUC0-∞) and (maximum serum concentration) Cmax with and without rHuPH20 was estimated using one-way analysis of variance."( Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20.
Bittner, B; Hussain, Z; McIntyre, C; Morcos, PN; Rowell, L; Zhang, X, 2013
)
0.39
" According to the results, both HI-6 salts applied in combination with hyaluronidase had increased tissue absorption and improved pharmacokinetic profile."( Hyaluronidase: its effects on HI-6 dichloride and dimethanesulphonate pharmacokinetic profile in pigs.
Chladek, J; Jun, D; Karasova, JZ; Kuca, K; Pavlik, M, 2013
)
0.39
"To demonstrate pharmacokinetic (PK) comparability for a single dose of 600 mg subcutaneous (SC) trastuzumab, administered via a novel single-use injection device (SID) or handheld syringe in 119 randomized healthy male subjects."( Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males.
Cranshaw, NA; Dick, AE; Ellis-Pegler, RB; Heinzmann, D; Lehle, M; Li, C; Lum, BL; Mangat, R; Schwabe, C; Waaka, DS; Wynne, CJ, 2013
)
0.39
"Based on preclinical results in minipigs, a Phase I study was designed to assess the tolerability and pharmacokinetic properties of subcutaneous ondansetron + rHuPH20 compared with intramuscular, intravenous, or oral ondansetron monotherapy in healthy volunteers."( Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.
Bahn, JD; DeNoia, E; Dychter, SS; Fellows, D; Harrigan, R; Haughey, DB; Maneval, DC; Printz, MA; Sugarman, BJ, 2014
)
0.4
" Primary tolerability end points (administration-site observations, systemic adverse events [AEs], and subject-assessed pain) were assessed, and pharmacokinetic parameters (AUC, Cmax, Tmax, t½) were computed to compare relative rate and extent of systemic exposure."( Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.
Bahn, JD; DeNoia, E; Dychter, SS; Fellows, D; Harrigan, R; Haughey, DB; Maneval, DC; Printz, MA; Sugarman, BJ, 2014
)
0.4
" The Cmax (45."( Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.
Bahn, JD; DeNoia, E; Dychter, SS; Fellows, D; Harrigan, R; Haughey, DB; Maneval, DC; Printz, MA; Sugarman, BJ, 2014
)
0.4

Compound-Compound Interactions

ExcerptReferenceRelevance
"In a prospective pilot study 21 patients with advanced squamous cell carcinoma of the head and neck were treated with polychemotherapy and Hyaluronidase combined with radiation."( [Cisplatin, vindesine and hyaluronidase combined with simultaneous radiotherapy of advanced head and neck tumors].
Allmayer, H; Klocker, J; Rab, B; Schumer, J; Tidstrand, J, 1990
)
0.28
"An ELISA-based microtiter-technique is used to evaluate the activity of hyaluronidase in combination with local anaesthetics, corticosteroids, NaCl 10%, and iodinated contrast media."( Experimental evaluation of hyaluronidase activity in combination with specific drugs applied in clinical techniques of interventional pain management and local anaesthesia.
Bader, R; Bittorf, T; Kundt, G; Mittelmeier, W; Schulze, C; Walzel, H,
)
0.13
"Microtiter plates were coated with biotinylated hyaluronate and incubated with hyaluronidase in combination with the above-mentioned drugs."( Experimental evaluation of hyaluronidase activity in combination with specific drugs applied in clinical techniques of interventional pain management and local anaesthesia.
Bader, R; Bittorf, T; Kundt, G; Mittelmeier, W; Schulze, C; Walzel, H,
)
0.13
"Tocilizumab in combination with rHuPH20 resulted in slightly increased tocilizumab exposure compared with tocilizumab alone, whereas PD markers were comparable."( Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20.
Bittner, B; Hussain, Z; McIntyre, C; Morcos, PN; Rowell, L; Zhang, X, 2013
)
0.39
" In conclusion, we presented an effective and practical IHC protocol for bone specimens characterized by H+P predigestion combined with AP-mediated chromogenic detection."( An effective and practical immunohistochemical protocol for bone specimens characterized by hyaluronidase and pepsin predigestion combined with alkaline phosphatase-mediated chromogenic detection.
Li, S; Liu, B; Rong, L; Tian, M; Tickner, J; Xu, J; Zhang, L, 2015
)
0.42
"LL-37 is the only human cathelicidin-family host defense peptide and has been reported to interact with invading pathogens causing inflammation at various body sites."( LL-37 alone and in combination with IL17A enhances proinflammatory cytokine expression in parallel with hyaluronan metabolism in human synovial sarcoma cell line SW982-A step toward understanding the development of inflammatory arthritis.
Chomdej, S; Jaitham, R; Kongdang, P; Kuensaen, C; Ongchai, S; Sirikaew, N; Thonghoi, S, 2019
)
0.51
"Recently, photodynamic therapy (PDT) emerges as a promising way to initiate immune response and being used in combination with chemotherapy."( Sequentially responsive biomimetic nanoparticles with optimal size in combination with checkpoint blockade for cascade synergetic treatment of breast cancer and lung metastasis.
Gao, H; He, X; Liu, R; Qin, L; Xiao, W; Xie, R; Yang, X; Yang, Z; Yu, W, 2019
)
0.51
"This meta-analysis was performed to systematically evaluate the efficacy of hyaluronidase combined with corticosteroids compared with other drugs in improving maximum mouth opening and alleviating the burning sensation in patients with oral submucous fibrosis (OSF)."( Efficacy of hyaluronidase combined with corticosteroids in treatment of oral submucous fibrosis: A meta-analysis of randomized controlled clinical trials.
Guo, J; Liang, M; Mao, S; Wu, H; Xie, H, 2020
)
0.56
"According to this meta-analysis, weak evidence indicates that hyaluronidase combined with corticosteroids has no additional clinical benefit over control drugs (lycopene, pentoxifylline, aloe vera, dexamethasone, Turmix and isoxsuprine) in improving maximum mouth opening and alleviating the burning sensation in patients with OSF."( Efficacy of hyaluronidase combined with corticosteroids in treatment of oral submucous fibrosis: A meta-analysis of randomized controlled clinical trials.
Guo, J; Liang, M; Mao, S; Wu, H; Xie, H, 2020
)
0.56
" PVHA appeared to demonstrate an acceptable safety profile when given with docetaxel without significantly changing the plasma PK of docetaxel in patients with stage IIIB/IV NSCLC."( Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non-small cell lung cancer.
Baumgart, M; Fathallah, AM; Gabrail, N; Heineman, T; Mager, DE; Maneval, DC; Nanavati, C; Sekulovich, RE; Van Wart, SA, 2021
)
0.62
" The results show that elimination of the hyaluronic acid barrier combined with the doxorubicin-loaded nanoprobes can greatly increase drug penetration into tumor tissue and improve the effectiveness of chemotherapy drugs."( Decreasing hyaluronic acid combined with drug-loaded nanoprobes improve the delivery and efficacy of chemotherapeutic drugs for pancreatic cancer.
Deng, H; Fan, YF; Guo, KX; Lu, GH; Shang, WT; Tian, J; Wang, CC; Zhu, XH, 2021
)
0.62
"The objective of this study was to determine the efficacy of curcumin in combination with  intralesional dexamethasone with hyaluronidase in the treatment of oral submucous fibrosis (OSF)."( Efficacy of Curcumin in Combination with Intralesional Dexamethasone with Hyaluronidase in the Treatment of Oral Submucous Fibrosis: A Randomized Controlled Trial.
Adhikari, S; Maharjan, IK; Rimal, J; Shrestha, A, 2022
)
0.72
"Curcumin in combination with intralesional dexamethasone with hyaluronidase is efficacious in the treatment of OSF."( Efficacy of Curcumin in Combination with Intralesional Dexamethasone with Hyaluronidase in the Treatment of Oral Submucous Fibrosis: A Randomized Controlled Trial.
Adhikari, S; Maharjan, IK; Rimal, J; Shrestha, A, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" It is concluded that hyaluronidase increases the rate of absorption of succinylcholine chloride."( The effects of hyaluronidase on the immobilization of goats by intramuscular succinylcholine chloride.
McLaughlin, HJ; Ohanesian, N; Swaim, SF; Ward, FP, 1969
)
0.25
" In particular, rHuPH20 changed the pharmacokinetic profiles and significantly augmented the absolute bioavailability of locally injected large protein therapeutics."( A recombinant human enzyme for enhanced interstitial transport of therapeutics.
Bookbinder, LH; Edgington, TS; Frost, GI; Haller, MF; Hofer, A; Keller, GA; Lim, JE; Patton, JS; Shepard, HM; Zepeda, ML, 2006
)
0.33
" The application of this technology to increase both injection volumes and bioavailability from subcutaneous injection may overcome some key limitations of this route of administration in multiple settings of care."( Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration.
Frost, GI, 2007
)
0.34
" Degradation of HS proteoglycans decreased NO bioavailability through an increase in O(2)(-) production as indicated by fluorescent signals of dihydroethidium (DHE) and its area fraction (209+/-24% increase) and also removed extracellular O(2)(-) dismutase (ecSOD) (67+/-9% decrease)."( Role of glycocalyx in flow-induced production of nitric oxide and reactive oxygen species.
Kassab, GS; Kumagai, R; Lu, X, 2009
)
0.35
" Concomitant SC administration of rHuPH20 enhanced the absorption rate of morphine compared with SC morphine with placebo, significantly reducing the mean T(max) from 13."( The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness.
Flament, J; Haller, MF; Thomas, JR; Vaughn, DE; Wallace, MS; Yocum, RC, 2009
)
0.35
" For example, hyaluronidase-facilitated administration increases the bioavailability of SCIg, and may allow for the administration of larger volumes at a single site."( Subcutaneous immunoglobulin: opportunities and outlook.
Berger, M; Borte, M; Misbah, S; Ochs, HD; Shapiro, RS; Sturzenegger, MH; Wasserman, RL, 2009
)
0.35
" The bioavailability of IGHy measured by area under the concentration versus time curve was 93."( Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.
Empson, VG; Engl, W; Gelmont, D; Gupta, S; Leibl, H; McCoy, B; Melamed, I; Puck, J; Schiff, RI; Stein, MR; Wasserman, RL, 2012
)
0.38
" Bioavailability calculated as AUCtotal (HI-6 DMS with hyaluronidase, 4,119 ± 647 min μg/ml) was also significantly higher compared to HI-6 DMS (2,259 ± 329 min μg/ml) and HI-6 dichloride (1,969 ± 254 min μg/ml); both without hyaluronidase."( Hyaluronidase: its effects on HI-6 dichloride and dimethanesulphonate pharmacokinetic profile in pigs.
Chladek, J; Jun, D; Karasova, JZ; Kuca, K; Pavlik, M, 2013
)
0.39
" Most relevant in practice is the co-application of hyaluronidase and other active substances in order to enhance their bioavailability within the tissue."( Use of hyaluronidase for pharmacokinetic increase in bioavailability of intracutaneously applied substances.
Wohlrab, A; Wohlrab, C; Wohlrab, D; Wohlrab, J; Wohlrab, L, 2014
)
0.4
" When applied as an adjuvant, hyaluronidase enhances the diffusion capacity and bioavailability of injected drugs."( Hyaluronidase: from clinical applications to molecular and cellular mechanisms.
Bölke, E; Buhren, BA; Gerber, PA; Hilton, S; Hoff, NP; Schrumpf, H, 2016
)
0.43
" Drugs based on hyaluronidase increase bioavailability of other drugs used in adjuvant therapy; they significantly increase effectiveness of treatment, and also provide targeted synthesis of hyaluronic acid, ths regulating the regeneration process of connective tissue."( [Peculiarities of the action of hyaluronidase of different origin to the connective tissue].
Danilova, TI; Habriyev, RU; Kakhoyan, EG; Kamayev, NO,
)
0.13
" In this article, we analyzed the bioavailability of hyaluronidase degradation of five fillers of Neauvia® hydrogels line (MatexLab SA, Lugano, CH), composed of pure hyaluronic acid and based on PEGDE cross-linking (polyethylene glycol) technology that guarantees a higher biocompatibility and an optimal biointegration and rheological characteristics."(
Esposito, C; Galadari, H; Maccario, C; Maggi, M; Mocchi, R; Passi, A; Rauso, R; Sommatis, S; Zerbinati, N, 2019
)
0.51
" Today, animal-derived bovine or ovine testicular hyaluronidases as well as synthetic hyaluronidases are clinically applied as adjuncts to increase the bioavailability of drugs, for the therapy of extravasations, or for the management of complications associated with the aesthetic injection of hyaluronic acid-based fillers."( Clinical Applications of Hyaluronidase.
Buhren, BA; Gerber, PA; Schrumpf, H; Weber, GC; Wohlrab, J, 2019
)
0.51
" The current study has therefore explored the lymphatic transport and bioavailability of cetuximab and trastuzumab after SC and ID coadministration in the presence and absence of rHuPH20 in rats."( Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats.
Brundel, DHS; Clift, R; Feeney, OM; Kang, DW; McIntosh, MP; Nguyen, TH; Porter, CJH; Styles, IK, 2019
)
0.51
" bioavailability was 66% and independent of dose or rHuPH20 co-administration."( Safety, Tolerability, and Pharmacokinetics of High-Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers.
Blondeau, K; Brooks, L; Carrasco-Triguero, M; Chesterman, A; Deshmukh, A; Dolton, MJ; Hu, N; Kerchner, GA; Moein, A; Ostrowitzki, S; Peng, K; Quartino, A; Roden, A; Sink, KM; Smith, J; Waitz, A; Wetzel-Smith, MK, 2021
)
0.62
" Its duration of effect may be longer than expected based on bioavailability of the HA product due to collagen synthesis or fibroblast stimulation."( Hyaluronic Acid Basics and Rheology.
Bloom, JD; Kam, J; Wu, GT, 2022
)
0.72
" However, the bioavailability of MNs was still far from the clinical requirements by only overcoming the stratum corneum barrier."( Hyaluronidase-powered microneedles for significantly enhanced transdermal delivery efficiency.
Chen, H; Chen, Y; Feng, D; Hu, W; Huang, Y; Pan, X; Peng, T; Ren, T; Wu, C, 2023
)
0.91
" This is a response to the circumvention of restrictions in the use of hesperidin due to its poor bioavailability resulting from low solubility and permeability."( Improving Solubility and Permeability of Hesperidin through Electrospun Orange-Peel-Extract-Loaded Nanofibers.
Cielecka-Piontek, J; Miklaszewski, A; Paczkowska-Walendowska, M, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" In contrast to the simple placebo test 25 patients, among them 12 cases with idiopathic panniculosis, could for the most part be treated successfully by highly dosed intravenous applications of hyaluronic acid."( [New possibilities in the treatment of panniculosis using hyaluronidase].
Kondziella, W, 1976
)
0.26
" In the dosage used in the man anaphylactic response is obviously rare though it is possible."( [Animal experimental studies on immunogenicity, humoral response and danger of anaphylaxis in parenteral administration of hyaluronidase].
Bellmann, H; Dellas, T; Storch, H, 1978
)
0.26
" Hyaluronidase could be of interest as a nucleolytic drug and needs further studies on optimal dosage and lack of side effects in the surrounding tissues before injecting it into human discs."( Experimental model of disc herniations in rats for study of nucleolytic drugs.
Amor, B; Kahan, A; Revel, M; Takenaka, Y,
)
0.13
"Several different strategies to improve the in vitro cytocidal effect of 5-fluorouracil/leucovorin (5FU/LV), including modulation of dosage and schedule and combination with other cytotoxic agents or biochemical modulators, were examined in the COLO 320DM and Ht-29 cell lines by means of the Bactec system."( A study of various strategies to enhance the cytotoxic activity of 5-fluorouracil/leucovorin in human colorectal cancer cell lines.
Scheithauer, W; Temsch, EM,
)
0.13
" Data are presented indicating that a) hyaluronic acid is required for the elevated migratory activity displayed by confluent fetal and breast cancer patient skin fibroblast; b) adult fibroblasts exhibit a bell-shaped dose-response to MSF, with maximal stimulation of migration observed at a concentration of 10 ng/ml; c) the migratory activity of adult fibroblasts pre-incubated with MSF remains high in the absence of additional factor: and d) MSF affects both the quantity and size class distribution of hyaluronic acid synthesized by adult fibroblasts."( Mechanism of action of the migration stimulating factor produced by fetal and cancer patient fibroblasts: effect on hyaluronic and synthesis.
Chen, J; Ellis, I; Grant, ME; Grey, AM; Rushton, G; Schor, AM; Schor, SL, 1989
)
0.28
" Reproducible dose-response relationships were developed for vinblastine (VBL) and vindesine (VDS)."( Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse.
Alberts, DS; Dorr, RT, 1985
)
0.27
" Modification of incubation temperature, thickness of agar layers, and host-phage input ratios resulted in a quantitative assay method having a dose-response range of 4 to 160 mug of anticapsin."( Anticapsin, a new biologically active metabolite: screening and assay procedures.
Denney, JW; Funderburk, SS; Lively, DH; Solenberg, JM; Westhead, JE; Whitney, JG, 1972
)
0.25
" A progessive reduction in testis weight with dosage was found after estrogen or the combination (p is less that ."( Effect of estrogen on biochemical composition of the rat seminiferous tubules.
Chowdhury, AR; Jehan, Q; Kamboj, VP; Kar, AB, 1971
)
0.25
"75% bupivacaine hydrochloride with hyaluronidase in adequate dosage greatly reduces the need for a seventh nerve block, thus reducing patient discomfort."( A technique of retrobulbar block with paralysis of orbicularis oculi.
Gills, JP; Loyd, TL, 1983
)
0.27
" There are no published dose-response studies of hyaluronidase used in this manner."( Hyaluronidase in the prevention of sclerotherapy-induced extravasation necrosis. A dose-response study.
Zimmet, SE, 1996
)
0.29
"To conduct a dose-response study using hyaluronidase in the prevention of necrosis following intradermal 23."( Hyaluronidase in the prevention of sclerotherapy-induced extravasation necrosis. A dose-response study.
Zimmet, SE, 1996
)
0.29
" A dose-response curve was constructed."( Hyaluronidase in the prevention of sclerotherapy-induced extravasation necrosis. A dose-response study.
Zimmet, SE, 1996
)
0.29
" The promising preclinical data and the rather well documented activity in therapeutic use as additive to local chemotherapy seem to be an adequate motive to further elucidate the complex manner in which hyaluronidase is active in the interstitial tumor matrix and to obtain more information concerning the optimal route of application, the optimal dosage and the spectrum of tumor entities where it is synergistic with cytostatic chemotherapy and perhaps even radiation therapy."( The impact of extracellular matrix on the chemoresistance of solid tumors--experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy.
Baumgartner, G; Gomar-Höss, C; Sakr, L; Ulsperger, E; Wogritsch, C, 1998
)
0.3
" Dosing experiments were performed for 3 months beginning at birth (6 hr/day for 5 days/week)."( Inhalation of diesel engine exhaust affects spermatogenesis in growing male rats.
Oonuki, Y; Watanabe, N, 1999
)
0.3
"Fifty female rats, weighing 200-220 g were randomly divided into the blank control group, the model group, the small dosage GZT group, the large dosage GZT group and the Biejiajian Pill (BJJP) group, 10 rats in each group."( [Experimental study on the anti-liver fibrosis effect of guzhang tablet in rats].
Liu, FZ; Yang, XP; Zhao, YY, 2003
)
0.32
"(1) Compared with the model group, the serum levels of alanine transaminase (ALT), aspartate aminotransferase (AST), glutamyltranspetidase (GGT), alkaline phosphatase (AKP) were improved in the GZT groups, better effect was got in the large dosage GZT group."( [Experimental study on the anti-liver fibrosis effect of guzhang tablet in rats].
Liu, FZ; Yang, XP; Zhao, YY, 2003
)
0.32
"To investigate the safety dosage of intravitreal injection of Plasmin, Hyaluronidase and their combination and to evaluate their efficacy in the formation of posterior vitreous detachment (PVD) through animal experiments."( [An experimental study on dissolving and detaching vitreoretinal interface with enzymes].
Cai, SZ; Liu, JZ; Lu, LC; Ma, JX; Wang, LF; Wang, ZD, 2004
)
0.32
" In safety dosage neither Hyaluronidase nor Plasmin alone were successful in producing completely posterior vitreous detachment (PVD), but the latter can produce partial PVD."( [An experimental study on dissolving and detaching vitreoretinal interface with enzymes].
Cai, SZ; Liu, JZ; Lu, LC; Ma, JX; Wang, LF; Wang, ZD, 2004
)
0.32
" extract at 4 and 400 mg/mL significantly increased keratinous moisture level with the increase in the number of dosing days, and caused no changes in transepidermal water loss."( [Anti-allergic action effect of Pseudolarix amabilis Rehd. extract and its efficacy on atopic dermatitis].
Higo, S; Hirasawa, Y; Iwasaki, S; Kyuki, K; Matsui, Y; Miwa, Y; Ohtsu, S; Ori, K; Shimizu, M; Yamada, T, 2004
)
0.32
" In addition to use for hydration, 6 patients received recombinant human hyaluronidase to enhance subcutaneous infusion of 9 medications, primarily because the medication dosage required subcutaneous flow rates greater than the standard 3 mL/hr."( Initial experiences with subcutaneous recombinant human hyaluronidase.
Pirrello, RD; Thomas, SH; Ting Chen, C, 2007
)
0.34
" Mean maximum plasma morphine concentration (C(max)) after SC dosing was 29% greater with rHuPH20 than without rHuPH20 (P=0."( The INFUSE-Morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers.
Flament, J; Haller, MF; Thomas, JR; Yocum, RC, 2009
)
0.35
"We review approved indications for injectable hyaluronidase and off-label uses as well as safety, efficacy and dosing information."( Hyaluronidase: a review of approved formulations, indications and off-label use in chronic pain management.
Day, M; Dunn, AL; Heavner, JE; Racz, G, 2010
)
0.36
" A description of the pharmacological action of each adjuvant is given followed by a review of randomised control trials, dosage and notable papers on the subject."( Adjuvants to local anaesthesia in ophthalmic surgery.
Adams, L, 2011
)
0.37
" Different dosage forms of the drug longidase were tested for efficacy in correction of impairment of structural and functional properties of erythrocytes, endothelial dysfunction and lipid peroxidation in the above patients."( [Structural and functional characteristics of erythrocytes, endothelial dysfunction and lipid peroxidation in patients with prostatic adenoma and comorbid chronic prostatitis].
Dolgareva, SA; Gavriliuk, VP; Konoplia, AI; Shatokhin, MN; Teodorovich, OV,
)
0.13
" PK and PD samples were collected after dosing and were estimated with non-compartmental methods."( Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20.
Bittner, B; Hussain, Z; McIntyre, C; Morcos, PN; Rowell, L; Zhang, X, 2013
)
0.39
"The co-primary PK endpoints area under the time-concentration curve from the start of dosing to day 22 (AUC(0-21 days)) and maximum observed trastuzumab serum concentration (C(max)) were dose-normalized and body-weight-adjusted, and compared using geometric mean ratios (GMRs)."( Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males.
Cranshaw, NA; Dick, AE; Ellis-Pegler, RB; Heinzmann, D; Lehle, M; Li, C; Lum, BL; Mangat, R; Schwabe, C; Waaka, DS; Wynne, CJ, 2013
)
0.39
" Subcutaneous dosing resulted in an extent of systemic exposure similar to that with intramuscular or intravenous dosing and greater than that with oral administration, and may be an option for clinical administration of ondansetron."( Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.
Bahn, JD; DeNoia, E; Dychter, SS; Fellows, D; Harrigan, R; Haughey, DB; Maneval, DC; Printz, MA; Sugarman, BJ, 2014
)
0.4
" When rHuPH20 was dosed with LPS, the induction of cytokines and chemokines was the same as LPS alone, but neutrophil infiltration was inhibited, likely by interrupting HA-CD44 interaction."( Recombinant human hyaluronidase PH20 does not stimulate an acute inflammatory response and inhibits lipopolysaccharide-induced neutrophil recruitment in the air pouch model of inflammation.
Chen, Y; Cowell, JA; Frost, GI; Huang, L; Huang, Z; Kultti, A; Rosengren, S; Shepard, HM; Thompson, CB; Wei, G; Zhao, C, 2014
)
0.4
" This feature allows a novel approach to be applied to the dosing schedule for this group of drugs with fixed doses being used instead of the initially developed weight- or body surface-adjusted dosing schedules."( Monoclonal antibodies: pharmacokinetics as a basis for new dosage regimens?
Azanza, JR; Gómez-Guiu, A; Sádaba, B, 2015
)
0.42
" Furthermore, the nanoprobe has also been employed to study the activity change of hyaluronidase affected by different concentrations of arsenate (a potential carcinogen), and the results show that even a low dosage of arsenate (50 μg/L) can raise the activity of hyaluronidase by about one-third, revealing the relationship between arsenate and the enzyme."( An upconversion luminescence nanoprobe for the ultrasensitive detection of hyaluronidase.
Li, L; Li, X; Ma, H; Shi, W; Song, Y; Wang, Z, 2015
)
0.42
" Alterations in the dosage of hyalurondiase during neocartilage fabrication can create constructs that have improved biomechanical properties for eventual surgical implantation."( Effect of hyaluronidase on tissue-engineered human septal cartilage.
Briggs, KK; Masuda, K; Reuther, MS; Sah, RL; Watson, D; Wong, VW, 2016
)
0.43
" The dosage of HYAL varies as the amount of ischemic tissue, consistent with the new underlying hypothesis that we must flood the occluded vessels with a sufficient concentration of HYAL for a sufficient period of time in order to dissolve the HA obstruction to the point where the products of hydrolysis can pass through the capillary beds."( New High Dose Pulsed Hyaluronidase Protocol for Hyaluronic Acid Filler Vascular Adverse Events.
DeLorenzi, C, 2017
)
0.46
" Dosage and the schedule of infusions provided sufficient immunoglobulin G (IgG) levels for the newborn baby."( A case report of pregnancy in a patient with common variable immunodeficiency emphasizing the need for personalized immunoglobulin replacement.
Jahnz-Różyk, K; Więsik-Szewczyk, E, 2018
)
0.48
"Food and Drug Administration (FDA)-approved in February 2019, SQ trastuzumab, a monoclonal antibody that binds to human epidermal growth factor receptor 2 (HER2) protein in combination with hyaluronidase, offers an alternative dosage form for patients with breast tumors overexpressing HER2."( Trastuzumab/Hyaluronidase-oysk: A New Option for Patients With HER2-Positive Breast Cancer.
Duco, MR; Murdock, JL; Reeves, DJ, 2020
)
0.56
" However, clear guidelines regarding the optimal dosage and mode of administration of HAase are missing, leaving a scientific gap for practitioners in their daily practice."( Multidose Hyaluronidase Administration as an Optimal Procedure to Degrade Resilient Hyaluronic Acid Soft Tissue Fillers.
Bourdon, F; Brusini, R; Faivre, J; Flégeau, K; Gallet, M; Jing, J; Moreno, C; Walker, L, 2023
)
0.91
" Differences in trough values between BMI groups and age groups (≤ 22%) may not warrant SCIG or fSCIG dose adjustments based on BMI or age alone; instead, the dosing paradigm should be guided by prior IVIG dose, individual IgG monitoring, and clinical findings."( Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.
Engler, F; Follman, K; Freshwater, E; Li, Z; Yel, L, 2023
)
0.91
"Hyaluronidase may preserve tissue flap vitality, starting at the bottom end of the dosage range."( The efficacy of hyaluronidase on flap survival: an animal model.
Cingi, C; Sungur, M; Yıldırım, C, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
purine nucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nrf2Homo sapiens (human)Potency15.84890.09208.222223.1093AID624171
glp-1 receptor, partialHomo sapiens (human)Potency5.01190.01846.806014.1254AID624417
TDP1 proteinHomo sapiens (human)Potency2.77160.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency5.62340.00527.809829.0929AID588855
67.9K proteinVaccinia virusPotency9.45630.00018.4406100.0000AID720579; AID720580
IDH1Homo sapiens (human)Potency5.80480.005210.865235.4813AID686970
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency20.48390.316212.443531.6228AID902; AID924
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency8.19950.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency125.89203.548119.542744.6684AID743266
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency0.35480.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency0.35480.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency0.35480.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency7.50240.004611.374133.4983AID624296; AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency25.11890.125912.234435.4813AID1458
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency22.38720.058010.694926.6086AID602310
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency35.48130.025911.239831.6228AID602313
Integrin beta-3Homo sapiens (human)Potency15.84890.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency15.84890.316211.415731.6228AID924
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A3Homo sapiens (human)Ki0.02200.00000.930610.0000AID340157
Adenosine receptor A3Rattus norvegicus (Norway rat)Ki0.74200.00030.91969.0000AID33337
Equilibrative nucleoside transporter 1Homo sapiens (human)IC50 (µMol)36.30780.00013.688363.0000AID330912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PAX8Homo sapiens (human)AC502.25000.04885.435469.1700AID687027
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (107)

Processvia Protein(s)Taxonomy
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
neurotransmitter uptakeEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleobase-containing compound metabolic processEquilibrative nucleoside transporter 1Homo sapiens (human)
xenobiotic metabolic processEquilibrative nucleoside transporter 1Homo sapiens (human)
neurotransmitter transportEquilibrative nucleoside transporter 1Homo sapiens (human)
xenobiotic transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
lactationEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleobase transportEquilibrative nucleoside transporter 1Homo sapiens (human)
adenine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleoside transportEquilibrative nucleoside transporter 1Homo sapiens (human)
purine nucleoside transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
cytidine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
uridine transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
adenosine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
inosine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
hypoxanthine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
thymine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
excitatory postsynaptic potentialEquilibrative nucleoside transporter 1Homo sapiens (human)
cellular response to glucose stimulusEquilibrative nucleoside transporter 1Homo sapiens (human)
cellular response to hypoxiaEquilibrative nucleoside transporter 1Homo sapiens (human)
pyrimidine-containing compound transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
transport across blood-brain barrierEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleoside transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
guanine transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
uracil transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
pyrimidine nucleobase transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
purine nucleobase transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (31)

Processvia Protein(s)Taxonomy
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
neurotransmitter transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleoside transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
adenine transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
guanine transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
uracil transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
purine nucleoside transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
cytidine transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
uridine transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
pyrimidine- and adenosine-specific:sodium symporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
plasma membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
basolateral plasma membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
apical plasma membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
presynapseEquilibrative nucleoside transporter 1Homo sapiens (human)
postsynapseEquilibrative nucleoside transporter 1Homo sapiens (human)
plasma membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID155531Inhibition of Trypanosoma brucei phosphoglycerate kinase (PGK); inactive at 4 mM2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Adenosine analogues as inhibitors of Trypanosoma brucei phosphoglycerate kinase: elucidation of a novel binding mode for a 2-amino-N(6)-substituted adenosine.
AID1481725Activation of FLAG tagged PINK1 (unknown origin) expressed in Flp-In TRex HEK293 cells co-expressing wild-type Parkin assessed as Parkin Ser65 phosphorylation at 50 uM after 24 hrs in absence of CCCP by immunoblotting analysis2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Kinetin Riboside and Its ProTides Activate the Parkinson's Disease Associated PTEN-Induced Putative Kinase 1 (PINK1) Independent of Mitochondrial Depolarization.
AID1430042Antiviral activity against TEBV Absettarov infected in PEK cells assessed as inhibition of viral reproduction preincubated with virus for 1 hr followed by addition to PEK cells measured after 1 hr by gentian violet staining based plaque reduction assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors.
AID1293511Selectivity index, ratio of CC50 for human RD cells to EC50 for Enterovirus 712016European journal of medicinal chemistry, Mar-23, Volume: 111Modification of the length and structure of the linker of N(6)-benzyladenosine modulates its selective antiviral activity against enterovirus 71.
AID340153Antitumor activity against human K562 cells after 48 hrs by MTS assay2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID340155Antitumor activity against human HT29 cells after 48 hrs by MTS assay2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID1430044Cytotoxicity against PEK cells after 7 days2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors.
AID31885Binding affinity to adenosine A1 receptor in rat brain membranes by measuring displacement of specific [3H]PIA as radioligand.1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID340156Antitumor activity against human MCF7 cells after 48 hrs by MTS assay2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID1175339Inhibition of collagen-induced human platelet aggregation after 3 mins by light transmission aggregometry2014Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24
Naturally occurring N(6)-substituted adenosines (cytokinin ribosides) are in vitro inhibitors of platelet aggregation: an in silico evaluation of their interaction with the P2Y(12) receptor.
AID25506Index of hydrophobicity (k')1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Dog coronary artery adenosine receptor: structure of the N6-aryl subregion.
AID330912Binding affinity to ENT1 transporter2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity.
AID340157Inhibition of human adenosine A3 receptor2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID1430041Antiviral activity against TEBV Absettarov infected in PEK cells assessed as inhibition of viral reproduction at 50 uM preincubated with virus for 1 hr followed by addition to PEK cells measured after 1 hr by gentian violet staining based plaque reduction2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors.
AID33337Binding affinity determined by displacement of specific binding of [125I]N-(4-amino-3-iodophenethyl)-adenosine in membranes of CHO cells stably transfected with the rat adenosine A3 receptor1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID340154Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1293510Cytotoxicity against human RD cells2016European journal of medicinal chemistry, Mar-23, Volume: 111Modification of the length and structure of the linker of N(6)-benzyladenosine modulates its selective antiviral activity against enterovirus 71.
AID30496Molar potency ratio (MPR) against adenosine A2 receptor of canine coronary artery1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Dog coronary artery adenosine receptor: structure of the N6-aryl subregion.
AID1293509Antiviral activity against Enterovirus 71 infected in human RD cells assessed as cell viability after 3 days by MTS assay2016European journal of medicinal chemistry, Mar-23, Volume: 111Modification of the length and structure of the linker of N(6)-benzyladenosine modulates its selective antiviral activity against enterovirus 71.
AID33792Binding affinity to adenosine A2A receptor in rat striatal membranes by measuring displacement of specific [3H]-CGS- 21680 as radioligand1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID1430043Cytotoxicity against PEK cells after 24 hrs2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8,080)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905022 (62.15)18.7374
1990's695 (8.60)18.2507
2000's854 (10.57)29.6817
2010's1083 (13.40)24.3611
2020's426 (5.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.36 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index5.22 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials280 (3.16%)5.53%
Trials0 (0.00%)5.53%
Reviews383 (4.32%)6.00%
Reviews2 (6.25%)6.00%
Case Studies217 (2.45%)4.05%
Case Studies0 (0.00%)4.05%
Observational3 (0.03%)0.25%
Observational0 (0.00%)0.25%
Other7,975 (90.03%)84.16%
Other30 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]